Title: Pregnancy with inflammatory disease: obstetric and rheumatology shared perspectives
Speaker: Dr Andrew Foote, Consultant Rheumatologist, Melbourne
Chairperson: Dr Kathy Paizis, Obstetric medicine physician and Nephrologist, Mercy Hospital for Women, Western Health Sunshine, Austin Health, Melbourne
Day: Sunday 13th October, 7:30am – 8:30am
Summary: Chronic inflammatory disease (CID) tends to be prevalent in women, with disease onset often overlapping peak reproductive age. As more women with CID choose to start a family, there is a need to discuss clinical care during this important time.
For many women disease activity may improve during pregnancy, though in approximately half of patients, this is not the case. Disease activity is associated with an increased risk of adverse pregnancy outcomes, and appropriate medical management is critical for optimising both fetal and maternal outcomes.
Families often face challenging questions related to the impact of active disease on themselves and the developing fetus, along with concerns about the safe use of medicines in pregnancy.
Biologic tumour necrosis factor inhibitors (TNFi) have demonstrated efficacy on the signs and symptoms of CID, however TNFi -amongst other treatments - are often discontinued prior to conception, at the time of pregnancy or during the second trimester to limit potential placental transfer to the fetus.
In this interactive symposium, presenters will discuss the management of women with CID.
- Pre-pregnancy planning - the importance of disease control
- Compatibility of medicines before, during and after pregnancy
- Recommendations for the use of biologics in pregnancy and breastfeeding
- What are the perspectives of clinicians and women with CID on their journey to motherhood (before, during and after pregnancy)
- Barriers to family planning and pregnancy in patients with CID
- Disease control before, during and after pregnancy
- Drug compatibility before, during and after pregnancy
- DMARD use (including biologics) in pregnancy and breastfeeding
- Current national and international recommendations for the treatment of women with CID, planning pregnancy, during pregnancy and postpartum
- UCB clinical data:
- In-utero exposure of infant to Certolizumab Pegol
- Level of Certolizumab Pegol in mature breast milk
- Maternal exposure to Certolizumab Pegol and pregnancy outcome data
Proudly Sponsored by UCB.